Decentralized proportional-integral controller based on dynamic decoupling technique using Beckhoff TwinCAT-3.1

An improved technique for the design of decentralized dynamic decoupled proportional-integral (PI) controllers to control many variables of column flotation was developed and implemented in this paper. This work was motivated by challenges when working with multiple inputs and multiple outputs (MIMO) systems that are not controllable by conventional linear feedback controllers. Conventional feedback control design consists of various drawbacks when it comes to complex industrial processes. The introduction of decentralization, decoupling, and many advanced controls design methods overcomes these drawbacks. Hence, the design and implementation of control systems that mitigate stability for MIMO systems are important. The developed closed-loop model of the flotation process is implemented in a real-time platform using TwinCAT 3.1 automation software and CX5020 Beckhoff programmable logic controllers (PLC) through the model transformation technique. The reasons for using the CX5020 as an implementation environment were motivated by the reliability, and is built according to new industry standards, allowing transformation, which makes it more advantageous to be used more than any other PLCs. This is done to validate the effectiveness of the recommended technique and prove its usability for any multivariable system. Comparable numerical results are presented, and they imply that industrial usage of this method is highly recommended

Decentralised PI controller design based on dynamic interaction decoupling in the closed-loop behaviour of a flotation process

An enhanced method for design of decenralised proportional integral (PI) controllers to control various variables of flotation columns is proposed. These columns are multivariable processes characterised by multiple interacting manipulated and controlled variables. The control of more than one variable is not an easy problem to solve as a change in a specific manipulated variable affects more than one controlled variable. Paper proposes an improved method for design of decentralized PI controllers through the introduction of decoupling of the interconnected model of the process. Decoupling the system model has proven to be an effective strategy to reduce the influence of the interactions in the closed-loop control and consistently to keep the system stable. The mathematical derivations and the algorithm of the design procedure are described in detail. The behaviour and performance of the closed-loop systems without and with the application of the decoupling method was investigated and compared through simulations in MATLAB/Simulink. The results show that the decouplers - based closed-loop system has better performance than the closed-loop system without decouplers. The highest improvement (2 to 50 times) is in the steady-state error and 1.2 to 7 times in the settling and rising time. Controllers can easily be implemented

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: protocol for an open-label randomized controlled trial

The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial demonstrated a 39% reduction in HIV infection, with a 54% HIV reduction in women who used tenofovir gel consistently. A confirmatory trial is expected to report results in early 2015. In the interim, we have a unique window of opportunity to prepare for and devise effective strategies for the future policy and programmatic scale-up of tenofovir gel provision. One approach is to integrate tenofovir gel provision into family planning (FP) services. The CAPRISA 008 implementation trial provides an opportunity to provide post-trial access to tenofovir gel while generating empiric evidence to assess whether integrating tenofovir gel provision into routine FP services can achieve similar levels of adherence as the CAPRISA 004 trial. This is a two-arm, open-label, randomized controlled non-inferiority trial. A maximum of 700 sexually active, HIV-uninfected women aged 18 years and older who previously participated in an antiretroviral prevention study will be enrolled from an urban and rural site in KwaZulu-Natal, South Africa. The anticipated study duration is 30 months, with active accrual requiring approximately 12 months (following which an open cohort will be maintained) and follow-up continuing for approximately 18 months. At each of the two sites, eligible participants will be randomly assigned to receive tenofovir gel through either FP services (intervention arm) or through the CAPRISA research clinics (control arm). As part of the study intervention, a quality improvement approach will be used to assist the FP services to expand their current services to include tenofovir gel provision. This protocol aims to address an important implementation question on whether FP services are able to effectively incorporate tenofovir gel provision for this at-risk group of women in South Africa. Provision of tenofovir gel to the women from the CAPRISA 004 trial meets the ethical obligation for post-trial access, and helps identify a potential avenue for future scale-up of microbicides within the public health system of South Africa. This trial was registered with the South Africa Department of Health (reference: DOH-27-0812-4129) and ClinicalTrials.gov (reference: NCT01691768) on 05 July 2012

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.

CAPRISA, 2014.Background: The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial demonstrated a 39% reduction in HIV infection, with a 54% HIV reduction in women who used tenofovir gel consistently. A confirmatory trial is expected to report results in early 2015. In the interim, we have a unique window of opportunity to prepare for and devise effective strategies for the future policy and programmatic scale-up of tenofovir gel provision. One approach is to integrate tenofovir gel provision into family planning (FP) services. The CAPRISA 008 implementation trial provides an opportunity to provide post-trial access to tenofovir gel while generating empiric evidence to assess whether integrating tenofovir gel provision into routine FP services can achieve similar levels of adherence as the CAPRISA 004 trial. Methods/design: This is a two-arm, open-label, randomized controlled non-inferiority trial. A maximum of 700 sexually active, HIV-uninfected women aged 18 years and older who previously participated in an antiretroviral prevention study will be enrolled from an urban and rural site in KwaZulu-Natal, South Africa. The anticipated study duration is 30 months, with active accrual requiring approximately 12 months (following which an open cohort will be maintained) and follow-up continuing for approximately 18 months. At each of the two sites, eligible participants will be randomly assigned to receive tenofovir gel through either FP services (intervention arm) or through the CAPRISA research clinics (control arm). As part of the study intervention, a quality improvement approach will be used to assist the FP services to expand their current services to include tenofovir gel provision. Discussion: This protocol aims to address an important implementation question on whether FP services are able to effectively incorporate tenofovir gel provision for this at-risk group of women in South Africa. Provision of tenofovir gel to the women from the CAPRISA 004 trial meets the ethical obligation for post-trial access, and helps identify a potential avenue for future scale-up of microbicides within the public health system of South Africa. Trial registration: This trial was registered with the South Africa Department of Health (reference: DOH-27-0812-4129) and ClinicalTrials.gov (reference: NCT01691768) on 05 July 2012

Data from: HIV testing in a South African emergency department: a missed opportunity

Background: South Africa (SA) has the highest burden of HIV infection in the world. Even though HIV testing is mandated in all hospital-based facilities in SA, it is rarely implemented in the emergency department (ED). EDs are episodic care centers that provide care to large volumes of undifferentiated patients for short periods of time, and may treat undiagnosed HIV-infected patients not captured through standard clinic based screenings. Methods and Findings: In this prospective study, we implemented the National South African HIV testing guidelines, including 24-hours a day counselor initiated HIV Counseling and Testing (HCT), at Frere Hospital in the Eastern Cape from September 1 to November 30, 2016. All patients that presented for care in the ED during the study period, and who were clinically stable and fully conscious, were eligible to be approached by HCT staff to receive a rapid point-of-care HIV test. A total of 2355 of the 9583 (24.6%) patients that presented to the ED for care during the study period were approached by the HCT staff, of whom 1852 were enrolled in the study. There was high uptake of HIV testing (78.6%) among a predominantly male (58%) patient group that mostly presented with traumatic injuries (70.8%). Four hundred (21.6%) of the enrolled patients were HIV positive, including 115 (6.2%) with previously undiagnosed HIV infection. The overall prevalence of HIV infection in females (29.8%) was twice that compared to males (15.4%), despite the burden of undiagnosed infection being similar (6.0% for all females and 6.4% for all males). Conclusions: Overall there was a high HIV testing uptake that revealed a significant burden of undiagnosed HIV infection in this setting, especially in young males. Future research should focus on testing optimization, and efficient linkage to care from the ED for antiretroviral therapy initiation

Relative likelihood of new diagnosis of HIV infection among all HIV positive patients.

<p>Relative likelihood of new diagnosis of HIV infection among all HIV positive patients.</p

Patient enrollment and testing acceptance overview.

<p>Patient enrollment and testing acceptance overview.</p

Characteristics of all participants stratified by testing acceptance (N = 2355).

<p>Characteristics of all participants stratified by testing acceptance (N = 2355).</p

Characteristics of participants who consented to HIV testing or knew their HIV status, stratified by HIV status (N = 1852).

<p>Characteristics of participants who consented to HIV testing or knew their HIV status, stratified by HIV status (N = 1852).</p